GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The widespread prevalence of obesity and its adverse health effects have made sustained weight loss strategies a public health priority. While the causes of obesity are still debated, 1 it is well established that a chronic positive or negative energy balance results in weight gain or loss, respectively. Caloric restriction (CR) with optimal nutrition has the potential to reverse several obesity-related metabolic complications, such as type 2 diabetes mellitus (T2DM), hepatic steatosis and hypertension.2 Challenges in implementing long-term CR regimens, such as low adherence, psychological impact and metabolic adaptation, have made the search for pharmacological alternatives an attractive area of research, though progresses in this field have, until recently, been limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Across trials, approximately 25–40% of total weight loss has been attributed to lean mass reduction, underscoring the importance of muscle-preserving strategies in older women.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muscle–Organ Crosstalk: The Emerging Roles of Myokines
Severinsen, M. C. K., & Pedersen, B. K. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa016 · Cited by 1,226
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 1×
“15 16 An example of successful combina - tion of GLP-1 RA with physical activity for a healthy weight loss in patients with obesity was shown by Lundgren et al , 17 where lean mass loss was minimised by a combined approach.”
Exercise and metabolic health: beyond skeletal muscle
Thyfault, J. P., & Bergouignan, A. (2020) · Diabetologia · doi:10.1007/s00125-020-05177-6 · Cited by 410
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391 · cited 1×
“11 12 Studies on metabolic surgery and CR show that, despite the muscle mass loss observed, weight reduction generally improves muscle function - ality (eg, insulin sensitivity) and phys - ical mobility.”
European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity, Tacke, F., Horn, P., Wong, V. W.-S., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06196-3 · Cited by 208 · cited 1×
“15 16 An example of successful combina - tion of GLP-1 RA with physical activity for a healthy weight loss in patients with obesity was shown by Lundgren et al , 17 where lean mass loss was minimised by a combined approach.”
Pareek, M., Schauer, P. R., Kaplan, L. M., Leiter, L. A., Rubino, F., & Bhatt, D. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.014 · Cited by 177
Herring, L. Y., Stevinson, C., Davies, M. J., Biddle, S. J., Sutton, C., Bowrey, D., & Carter, P. (2016) · Obesity Reviews · doi:10.1111/obr.12361 · Cited by 155
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025) · Obesity Reviews · doi:10.1111/obr.13841 · Cited by 149 · cited 2×
“8 Even in very- low-calorie ketogenic diets (VLCKD), which are char - acterised by higher lean mass loss due to the severity of CR, the former can be mitigated when this dietary approach is combined with resistance training and strategic protein intake.”
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
Understanding the cause of type 2 diabetes
Taylor, R. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00157-8 · Cited by 95
Cited by
Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G. (2026) · Nutrients · doi:10.3390/nu18040632 · Cited by 11
“This proportion of lean mass loss is of particular clinical concern in older women, particularly those with pre-existing sarcopenia or low baseline muscle reserves [53].”
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
Is weight cycling clinically harmful?
Magkos, F., & Stefan, N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00037-9 · Cited by 4
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“These potent systemic actions lead to a reduction in visceral adiposity and dramatically improve systemic metabolic control (Weghuber et al., 2022; Cusi et al., 2018; Cai et al., 2025; Mocciaro et al., 2025).”
Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy
Belančić, A., Skroče, K., Gkrinia, E. M. M., Glavić, M. M., & Kwok, M. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155870 · Cited by 3
Metadata
- Authors
- Mocciaro, G., Capodici, A., & De Amicis, R.
- Affiliations
- Foundation for Liver Research (GB)
- Scuola Superiore Sant'Anna (IT)
- IRCCS Istituto Auxologico Italiano, Obesity Unit and Laboratory of Nutrition and Obesity Research, Department of Endocrine and Metabolic Diseases, 20145 Milan, Italy, Milan, Italy
- Corresponding author
- Mocciaro, Gabriele
- Venue
- BMJ Nutrition, Prevention & Health
- Publisher
- BMJ
- Published
- 2025-03-03
- Volume
- 8
- Issue
- 1
- Pages
- 4-5
- ISSN
- 2516-5542 (ISSN-L)
- PMC
- PMC12322565
- OpenAlex
- W4408098160
- Cited by
- 9
- References
- 17
- Citations by year
- 2026: 9
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Nutrition Prevention & Health (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- CINECA IRIS Institutional Research Information System (Sant'Anna School of Advanced Studies) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, caloric restriction, lean mass loss, weight loss, obesity, energy balance, type 2 diabetes, hepatic steatosis, metabolic adaptation, pharmacological weight loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction. https://app.cochat.ai/papers/10.1136/bmjnph-2025-001206
- The paper
- Mocciaro, G., Capodici, A., & De Amicis, R. (2025). GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction. BMJ Nutrition, Prevention & Health. https://doi.org/10.1136/bmjnph-2025-001206
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.